AMPylation has been exclusively studied with the FICD protein 3-6 . Here we investigate the role of AMPylation in human neurogenesis by introducing a cell-permeable propargyl adenosine pronucleotide probe to infiltrate cellular AMPylation pathways and report distinct modifications in intact cancer cell lines, human-derived stem cells, neural progenitor cells (NPCs), neurons and cerebral organoids (COs) via LC-MS/MS as well as imaging methods. A total of 162 AMP modified proteins were identified. FICD-dependent AMPylation remodelling accelerates differentiation of neural progenitor cells into mature neurons in COs, demonstrating a so far unknown trigger of human neurogenesis. Introduction of protein PTMs is a tightly controlled and almost ubiquitous process that often modulates critical protein function. PTMs such as tyrosination, acetylation and neddylation are known to play a crucial role in the development of the nervous system and in particular of neurons by broadening the diversity of the tubulin and microtubule proteoforms 7, 8 .
AMPylation was first discovered in Escherichia coli as regulator of glutamine synthetase activity 9 . Later, it was found that bacterial effectors from Vibrio parahaemolyticus and Histophilus somni AMPylate Rho guanosine triphosphatases (GTPases) in human host cells 10, 11 . These bacterial effectors contain highly conserved Fic (filamentation induced by cAMP) domains, which catalyse the transfer of AMP onto a serine, threonine or tyrosine residue of a substrate protein (Fig. 1a ). Approximately 3,000 members of this family are known to contain the conserved HXFX(D/E)GNGRXXR sequence motif throughout all domains of life 12 .
Despite their abundance in bacteria, only one human protein AMPylator containing the signature Fic domain, termed FICD (also known as Huntingtin yeast partner E, HYPE), has been discovered 12 . Structural and biochemical studies with FICD have revealed that its activity is tightly regulated and controlled by an autoinhibitory loop. Mutation of E234 to glycine overrides autoinhibition and results in a constitutively activated enzyme 12 ; the mutant form H363 to alanine is catalytically inactive 4 . One known substrate of FICD is HSPA5, which is a chaperone located in the endoplasmic reticulum (ER) and master regulator of the unfolded protein response (UPR) [3] [4] [5] [6] . Recent data show that FICD regulates the ATPase activity of HSPA5 and its interactions with unfolded proteins, but the exact function is not yet clear 13 . However, it was found that the HSPA5 AMPylation associates with changes in neuronal fitness in drosophila 3, [14] [15] [16] .
Just recently, the highly conserved pseudokinase selenoprotein-O (SelO) was found to possess AMP transferase activity in eukaryotic cells 17 . Pseudokinases account for about 10% of the human kinome but lack the characteristic active site residues and hence their function is largely unknown. However, their putative AMPylation activity is pointing to a possibly larger number of AMPylated proteins in human cells.
Lately, N 6 -propargyl adenosine-5'-O-triphosphate (N 6 pATP)-derived probes have been applied to profile substrates of AMPylation in cell lysate [18] [19] [20] . Nevertheless, the most pressing, unaddressed challenge in discovering the function of AMPylation is the global analysis of AMPylated substrates under physiological conditions inside living cells. Particularly, ATPderived probes suffer from restricted uptake of the charged nucleotides as well as competition with high endogenous ATP levels. Thus, new concepts are urgently needed to unravel the function of AMPylation in eukaryotic cells. Here we present a chemical-proteomic approach for identification of protein AMPylation in living cells using a pronucleotide probe and uncover FICD-dependent AMPylation remodelling responsible for acceleration of neuronal differentiation in cerebral organoids (COs).
Results

6-Propargyl adenosine pronucleotide reports on protein AMPylation.
To approach the challenge of identifying AMPylated proteins in situ, we selected a phosphoramidate pronucleotide strategy (Fig. 1a, b) 21 . This delivery method not only enhances the probes' cell membrane permeability but also bypasses the first phosphorylation of the nucleoside analogue by kinases. Based on these considerations, we designed and synthesized a N 6 -propargyl adenosine phosphoramidate pronucleotide (pro-N6pA, Fig. S1 ). We initiated our investigations with metabolomics experiments to determine pro-N6pA in situ metabolic activation to the corresponding N6pATP. A maximum concentration is reached 8 hours after pro-N6pA addition and it is maintained for at least 24 hours ( Fig. S2 ). For the subsequent analysis of AMPylated proteins, we treated living (intact) HeLa cells with pro-N6pA (100 µM in DMSO) or dimethylsulfoxide (DMSO). Subsequent click-chemistry to a rhodamine-biotin-azide tag, enrichment on avidin beads and SDS-PAGE analysis via in-gel fluorescence detection revealed several distinct protein bands in the soluble fraction ( Fig. 1c ). Next, we performed quantitative proteome profiling in HeLa cells 22 . Enriched proteins were trypsin digested and resulting peptides were either isotopically marked by dimethyl labelling (DiMe) prior to LC-MS/MS measurement or analysed directly using label-free quantification (LFQ) ( Fig. 1d) 23, 24 .
Comparing pro-N6pA labelling ( Fig. 1e ) with parent N 6 -propargyl adenosine (N6pA, Fig. 1f , Using pro-N6pA, a diverse group of 19 proteins were identified in HeLa cells, including the known FICD substrate HSPA5 ( Fig. 1e , Table S1 ). Immunoprecipitation of the two selected proteins PFKP and PPME1 from the probe treated HeLa cells followed by click reaction with rhodamine-azide tag confirmed incorporation of the probe into these proteins (Fig. S3 ).
Although the N 6 -propargyl ATP analogue could, in principle, serve as precursor for ADP-ribosylation 25 , our controls indicate that ADP-ribosylation is not a major route. ADPribosylation is usually induced by stress conditions e.g. by addition of hydrogen peroxide to the cells' media 26 . First, HeLa cells were pre-treated with poly(ADP-ribose)polymerases (PARP) inhibitors 4-aminobenzamide (4-ABA) or olaparib (Ola) prior to pro-N6pA labelling. For both PARP inhibitors, no influence on labelling intensity was observed based on in-gel fluorescence analysis ( Fig. S3 ). In addition, MS-based chemical-proteomic experiments with Ola and pro-N6pA treated cells confirmed no changes in AMPylation ( Fig. 1g and Table S2 ). Second, only two of our identified AMPylated proteins in HeLa cells (HIST1H2AH, RPS10) matched known ADP-ribosylated proteins (Fig. S3 ) 27 . Known ADP-ribosylated proteins were excluded as potential hits in the following experiments (Table S3 ). 
AMPylation of cathepsin B inhibits its peptidase activity in vitro.
In order to validate our approach in more detail, we have employed an azide-TEV-cleavable-biotin linker during the pull-down procedure to identify the corresponding AMPylation sites of modification via MS/MS ( Fig. 2a , b) 28 . We were able to directly analyse AMPylated peptides on three different cysteine cathepsin proteases CTSB (S104 and S107), CTSC (S254) and CTSL (S137) in HeLa cells ( Fig. S4 and S5 ). All of the AMPylation sites were located on serine residues within the conserved sequence surrounding the catalytically active cysteine ( Fig. 2c ), suggesting that the bulky AMP modification might obstruct the binding of the peptide substrates and thus inhibit protease activity 29 . To determine whether FICD is the AMPylator of these cathepsins, we used an in vitro peptidase activity assay and found that cathepsin B is indeed inhibited upon FICD (wild-type (wt) or E234A mutant) treatment and did not observe any inhibition without the addition of ATP ( Fig. 2d, Fig. S4 ). The direct measurement of AMPylation sites in CTSB (S104,107) in vitro was restricted by preparation of the recombinant double mutant CTSB which did not fold into the active protein, likely due to the mutation of the crucial amino acid residues within the conserved active site. Moreover, the TEV-linker based enrichment of modified peptides was performed with other cell types used in this study and three additional sites on MYH9, RAI14 and AASS (on Thr, Ser and Tyr residues respectively) were detected (Table S4 ). Of note, the MS-based identification of AMPylated sites in living cells is limited by the endogenous degree of modification. We thus assume that site identifications of proteins with lower AMP abundance are challenged by the detection limit. Here, previous trials in cell lysates using an active recombinant FICD E234G mutant yielded a complementary set of proteins likely due to an increased degree of modification ( Fig. S6 and Table S5) 20 . Two-tailed Student's t-test; ** < 0.01, **** < 0.0001.
Chemical-proteomics profiling shows cell type dependent AMPylation pattern and in part
independency of FICD. We performed proteome profiling in three different cancer cell lines, HeLa, A549 and SH-SY5Y, which revealed a total of 58 significantly enriched proteins, of which 38 were contributed solely from the latter neuroblastoma cells ( Fig. 3a, Fig. S7 ). Overall, AMPylated proteins identified here are involved in diverse metabolic pathways including a widely conserved key regulator of glycolysis ATP-dependent 6-phosphofructokinase (PFKP) 30 , proteolysis (CTSA, CTSB) 31 , regulation of PTMs (PPME1) 32 and UPR (HSPA5 and SQSTM1) 33 . Intriguingly, only PFKP was found to be AMPylated in all three cell lines, which otherwise exhibited unique AMPylation patterns.
To directly dissect the descent of AMPylated proteins from FICD, we compared the AMPylation levels of proteins in probe treated HeLa cells comprising FICD knockdown, wt FICD overexpression (OX) and activated FICD E234G OX (Fig. 3b, Fig. S8 and Table S6 ).
Interestingly, HSPA5 is a clear FICD-dependent responder where AMPylation is significantly upregulated in FICD E234G OX and downregulated in wt FICD OX, which is also known to perform de-AMPylation 6 . Remarkably, while all previous studies have been carried out in vitro [18] [19] [20] , we here independently confirm this data by the first in situ experiments. A direct in situ interaction is further corroborated by MS-based pulldown experiments of wt FICD and FICD E234G in the presence of a chemical crosslinker, which revealed HSPA5 together with other sets of proteins as interacting partners, while proteins like SQSTM1, PFKP and PPME1
were not enriched and thus considered as not interacting with FICD ( Fig. 3c) 34 . Of note, FICD E234G revealed a more pronounced interaction with HSPA5, confirming our OX studies ( Fig.   S9 and Table S7 ). GO term analysis of the overlapping interacting partners indicated a link to basal metabolism ( Fig. 3d ). With HSPA5 as a validated candidate, we moved on and analysed other AMPylated proteins. The set of hits including PPME1, PFKP and SQSTM1 exhibited no significant changes in AMPylation levels upon FICD KD and OX, suggesting an FICDindependent mode of AMPylation ( Fig. 3b ) for which the origin of the AMP transfer could not be fully deduced. Given the recent discovery of an additional AMPylating enzyme also in eukaryotic cells, it is likely that the other proteins detected here descent form (a) yet undiscovered AMPylator(s) 17 .
Next, proteome profiling under endoplasmic reticulum (ER) stress conditions was performed to determine whether modifications are altered as previously reported for thapsigargin (Tg)-treated cells 6 . Only a slight increase by 2.5-fold in AMPylated HSPA5 was observed in HeLa and A549 cells. Quantification of HSPA5 by western blot shows an increase in HSPA5 expression by more than 11-fold after Tg treatment. Thus, normalization of total AMPylation to the expression of HSPA5 results in an overall reduction of its AMPylation, which is in line with previously published results ( Fig. S7) 6 . Despite the moderate impact of ER stress on AMPylation in these cells, we found 145 dysregulated proteins in SH-SY5Y neuroblastoma cells (Fig. S7 ). The high amount of AMPylated proteins in SH-SY5Y under baseline and ER stress conditions indicates that AMPylation may have a specific role in the nervous system. Table S1 and S8). While PFKP was AMPylated in both the proliferating cell lines and neurons, the proteins CTSB, PSAT1 and PPME1 were only AMPylated in proliferating cells. Importantly, neurons exhibited the largest number of significantly and differentially AMPylated proteins (55 total), including transport proteins (KIF21A, KIF5C, MYH3, MYH7, MYH8) and cytoskeletal proteins (TUBB, TUBB2B, TUBB3B, TUBB4B, MAP2) ( Fig. 4a ). This is of particular interest as the cytoskeletal remodelling, which is required for neuronal polarisation, migration, and proper axon guidance, is a highly dynamic processes precisely regulated by several PTMs on tubulin and microtubules -and AMPylation may indeed be an additional one ( Fig. S13) 7, 8, 36, 37 . AMPylation remodelling could be involved in the process of cell type specification and differentiation from iPSCs through NPCs to neurons, with cellular proteins undergoing substantial de-and re-AMPylation following an hourglass-like model (Fig. 4b, Fig. S11 NPCs and neurons ( Fig. 5, Fig. S15 and Table S9 ). In order to rule out signals derived from N 6propargyladenosine nucleotide incorporation into RNAs (e.g. in polyA tails of mRNA) 38 , we performed a control experiment in which the RNA of the fixed cells was digested with different concentrations of RNase prior to click-chemistry and as positive control of the RNase digest 5ethynyl uridine (5-EU) stained RNAs were degraded in parallel to pro-N6pA labelling. Indeed, we observed only a slight decrease in overall cell staining by pro-N6pA rather than disappearance of the bright AMPylation spots, while we observed a strong decrease in 5-EU labelling (Fig. S16) .
Given that the cellular localisation of FICD and AMPylated proteins might play an important functional role, we combined click chemistry with rhodamine-azide for intracellular probe visualisation with immunohistochemistry (IHC) for FICD and various cellular markers: PDI for rough endoplasmic reticulum, GM130 for Golgi complex, TUBB3 for total neuronal microtubule cytoskeleton, MAP2 for neuronal dendrites, phospho-TAU for neuronal axons, and DAPI to visualize nuclei (Fig. 5, Fig. S15 ). Staining performed in HeLa cells revealed that AMPylated proteins are enriched in the nucleus, additional small spots were found in the cytoplasm partially overlapping with the ER. As expected, FICD is localized in the ER but also present in the cytoplasm and nucleus (Fig. 5a ). This observation was further corroborated by overexpression of FICD with a C-terminal FLAG tag (Fig. S17) . On the contrary, in NPCs AMPylation strictly localized next to the rough ER and in the nucleus, while FICD is ubiquitously distributed (Fig. 5b, c) . In neurons, AMPylation was observed in nucleus and to a lesser extent in neurites, including MAP2+ dendrites and phospho-TAU+ axons ( Fig. 5d-g) .
Here, FICD is localized in the nucleus, cytoplasm as well as ER (Fig. 5d ). Finally, fibroblasts showed another specific localisation pattern with AMPylation accumulated around the nucleus and its' complete absence inside, while FICD is homogenously spread across the cells ( 
Decrease of FICD levels in in vitro neural model systems reveals a role of FICD-dependent
AMPylation remodelling in neuronal differentiation. To understand if FICD-mediated
AMPylation plays a role in neuronal differentiation, we utilized both NPC-to-neuron differentiation and the recently developed 3-dimensional human cerebral organoids (COs) 39, 40 .
COs contain areas which closely resemble the structure and organisation of the germinal zones of developing human neocortex (Fig. S18) 41 . Treatment of COs with pro-N6pA and subsequent analysis via LFQ LC-MS/MS confirmed the AMPylation of PFKP, found in all cell types, and CTSB, another prevalent target in other studied cell lines ( Fig. 4a and Fig. S5 and S12).
Analysis of the significantly enriched proteins using a STRING database revealed that several proteins are located in extracellular space (Fig. S13) . Interestingly, visualization of the pro-N6pA probe-treated COs via click-chemistry with rhodamine-azide revealed strongest fluorescence in the neuronal layer (Fig. 5i, j and Fig. S15 ), which is in line with the highest number of AMPylated proteins identified in neurons (Fig. 4a) .
To examine the function of AMPylation in neurogenesis and neuronal differentiation in more detail, we first characterized the expression of FICD in NPCs, neurons, neuroblastoma cells and COs and found a clear enrichment of FICD in the neurites of neurons, SH-SY5Y and in the neuronal layer of COs compared to the progenitor zone ( Fig. 5d, h; Fig. S15 ). Results of imaging were paralleled by qPCR studies demonstrating higher baseline expression levels of FICD in neurons compared to iPSCs and NPCs (Fig. S19 ). We knocked down FICD levels ( Fig.   S20 ) in NPCs differentiating to neurons (Fig. 6a, b) and found a significant increase in transfected cells that remain in cell cycle (KI67+) (Fig. 6a ). This result suggested a potential role of FICD-mediated AMPylation in neurogenesis. We then performed down-or upregulation of FICD expression in ventricle-like germinal zones of 50 days old COs by electroporation, as this model system better resembles the 3-dimensional organization of the developing brain.
Only apical radial glia cells (aRGs), which are bipolar neural stem cells that will subsequently give rise to intermediate progenitors and neurons directly, are capable of taking up the vectors via their apical process to the ventricle-like lumen (Fig. 6c ). To asses if FICD-mediated AMPylation has a function in neurogenesis during development, COs were analysed 7 ( Fig. 6 and 7, Fig. S21 ) and 14 days post-electroporation (dpe) (Fig. S22 ). Cortical-like germinal zones were defined by immunohistochemical (IHC) analysis using PAX6 as a marker for dorsal aRGs (Fig. 6d, Fig. 7b ) with mitotic cells labelled for PH3 ( Fig. 6e, Fig. S21 ). The position and number of neurons was analysed by IHC using two different markers for mature neurons:
MAP2, a microtubule-associated protein which is enriched in neuronal dendrites (Fig. 7c, Fig.   S21 ) and the nuclear marker NEUN (Fig. 6g, Fig. 7d ). Most of miRNA-transfected (GFP+) cells (FICD KD) were positive for PAX6 ( Fig. 6d ) 7 dpe. The proportion of mitotic PH3+GFP+ cells was significantly increased (Fig. 6e, f) at the expense of neurons, as shown by the significantly reduced number of NEUN+GFP+ cells (Fig. 6g, h) . 
Forced expression of FICD wt and E234G in vitro leads to an increased neuronal
differentiation. Conversely, when electroporating vectors carrying wt FICD, activated FICD E234G mutant or catalytically inactive FICD H363A mutant into ventricles of 50 days old COs, those transfected with FICD wt or E234G showed an increase and redistribution in fluorescent signal upon pro-N6pA treatment indicating a remodelling of AMPylation upon FICD overexpression (Fig. 7a) , while there were no changes in distribution or intensity of the signal upon OX of FICD H363A used as a control ( Fig. S21 and similarly in neuroblastoma cells Fig.   S23 ). Moreover, upon FICD wt or E234G OX in COs, progenitor zones had regions sparse in PAX6+ cells (Fig. 7b) . At the same time, MAP2+ neurites increasingly invaded these progenitor zones 7 dpe (Fig. 7c, blue arrowheads; Fig. S21 ) and 14 dpe (Fig. S22) , which was not the case upon control or FICD H363A electroporation (Fig. 7c) , nor upon FICD KD (Fig.   S21 ). Interestingly, both the E234G mutant and wt FICD-transfected aRGs gave rise to a significantly higher number of neurons compared to H363A inactive mutant or control already at 7 dpe (Fig. 7e, f) , which was consistent also at 14 dpe (Fig. S22) . Additionally, we have excluded other cellular processes to be involved in the observed effect by whole proteome analysis of FICD transfected neuroblastoma cells (Fig. S24 , Table S10 ), which showed only minimal changes in overall protein expression. Furthermore, pull-down of the AMPylated proteins from neuroblastoma cells under FICD E234G OX conditions revealed a general increase in AMPylation including proteins such as CTSB, TPP1, CAPZB and NSFL1C, which were found AMPylated in COs (Fig. S25 , Table S11 ). This effect was not observed with FICD wt OX, which is in line with low AMPylation activity of the FICD wt.
Taken together, FICD may regulate the transition from neural progenitors to neurons.
The direct comparison to catalytically inactive FICD H363A, showing no difference to control condition, demonstrates the importance of FICD catalytic activity in proper progenitor cell cycle exit and neuronal differentiation. These results suggest that remodelling of AMPylation may play a role in neuronal differentiation during human brain development. However, it remains to be investigated whether the specific AMPylation/de-AMPylation activity on HSPA5 and subsequent changes in the UPR are responsible for modulation of the neuronal differentiation, which would be supported by the known connection between UPR and brain development. 42 Alternatively, the synergistic action of AMPylation on cytoskeletal protein targets and associated changes in cellular polarization as described for example for MAP6 palmitoylation could be responsible for these effects. 43 With these features, we believe our method will lead to discovery of new functions for Mass Spectrometry. Nanoflow LC-MS/MS analysis was performed with an UltiMate 3,000
Nano HPLC system coupled to an Orbitrap Fusion or Q Exactive Plus (Thermo Fisher Scientific). Fragments were generated using higher-energy collisional dissociation (HCD) and detected in the ion trap at a rapid scan rate. Raw files were analysed using MaxQuant software with the Andromeda search engine. Searches were performed against the Uniprot database for Homo sapiens (taxon identifier: 9606, 7th July 2015, including isoforms). At least two unique peptides were required for protein identification. False discovery rate determination was carried out using a decoy database and thresholds were set to 1 % FDR both at peptide-spectrum match and at protein levels. For AMPylation site identification spectra were searched for AMP conjugated with TEV tag (+694.2700) and only one unique or razor peptide was required. For details of MS measurement and data analysis see Supplementary Information and Tables S1,   S4 and S8. 
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